News Focus
News Focus
Followers 42
Posts 5340
Boards Moderated 0
Alias Born 12/05/2021

Re: Galzus Research post# 771437

Friday, 06/13/2025 9:28:41 AM

Friday, June 13, 2025 9:28:41 AM

Post# of 828159
I unfortunately have to agree that the low stock performance of NWBO is due to a lack of confidence of management and the actions they have taken so far.
If NWBO had a normally functioning management then they could probably look forward to the same revenue outlook performance as Iovance.
Bets for patients, shareholders and management is that NWBO would be bought for $ 5-7 billion after MHRA approval and normal functioning management will take over.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News